Studying the treatment of NMRI mice with ip injections of bleomycin (BLM) for 5 days we found an approximate LD5° of 35 mg/kg; the toxicity of peplomycin (PEP) was slightly higher (LD50: approximately 25 mg/kg). The effect of the two drugs on growth of L5178y mouse lymphoma cells in NMRI mice was examined. BLM alone caused at a concentration of 2.5 mg/kg an almost complete inhibition of tumor cell growth; the same effect was determined with 1 mg PEP/kg. At these concentrations the drugs caused an increase of the survival time of 110% (BLM) or 104% (PEP). Given in combination, one-sixth of the optimal doses yielded an 100% increase of the median survival time. These results indicate a significant synergistic activity of the PEP-BLM combination on L5178y cell growth in vivo (FIC index: 0.34).
3-14-23 Kamiosaki, Shinagawa-ku, Tokyo, Japan (Received for publication September 22, 1983) Studying the treatment of NMRI mice with ip injections of bleomycin (BLM) for 5 days we found an approximate LD5° of 35 mg/kg; the toxicity of peplomycin (PEP) was slightly higher (LD50: approximately 25 mg/kg). The effect of the two drugs on growth of L5178y mouse lymphoma cells in NMRI mice was examined. BLM alone caused at a concentration of 2.5 mg/kg an almost complete inhibition of tumor cell growth; the same effect was determined with 1 mg PEP/kg. At these concentrations the drugs caused an increase of the survival time of 110% (BLM) or 104% (PEP). Given in combination, one-sixth of the optimal doses yielded an 100% increase of the median survival time. These results indicate a significant synergistic activity of the PEP-BLM combination on L5178y cell growth in vivo (FIC index: 0.34 The subacute toxicity tests were performed with 5 mice each. The drugs were applied by daily intraperitoneal injection for 5 days. Both normal mice and mice bearing L5178y cells (eight days after tumor inoculation) were used for this study.
The evaluation of the antitumor effects of BLM and PEP in L5178y leukemia was performed as follows: Mice were made leukemic by ip injection of 1.2 x 100 L5178y cells. Eight days later, the animals were divided into groups of 25 mice. One group was used as control, whereas the other groups were treated ip with BLM or PEP for five consecutive days. During and after the treatment, the body weight as well as the number of survivors were determined.
Statistical Evaluation T-test to determine the significance of the growth inhibition effects of different concentrations of the drugs was performed according to Student").
The mathematical evaluation of the fractional inhibitory concentration index (FIC index) of PEP-BLM combinations was performed according to published equations"" as applied earlier". The ED50 is that effective dose, which causes approximately a 50% reduction of tumor growth. Using L5178y bearing NMRI mice, both BLM and PEP caused a marked and significant inhibition of L5178y cell growth in vivo (Fig. 1) . The drugs were administered for 5 days (day 8 -12 after tumor inoculation). At day 20, BLM caused at a dose of 1.25 mg/kg a reduction of tumor growth from 144±17 % (based on body weight) to 137±16 %, at 2.5 mg/kg to 125 -_16 % (P<0.005) and at 5 mg/kg to 119±14% (P<0.005) (Fig. 1A) . Using PEP (Fig. 1B) a reduction from 145±18% to 132±15 (P<0.01) at 0.5 mg PEP/kg, to 127±14% (P<0.005) at 1 mg/kg and to 121±14% (P<0.005) at 2.5 mg/kg was measured. From these results, the therapeutic index (ratio of the approximate values of LD50 and of ED,,) for BLM was calculated to be 28 (35 mg/kg to 1.25 mg/kg). For PEP the therapeutic index was estimated to be 50 (25 mg/kg to 0.5 mg/kg).
The inhibition of tumor growth in the ascites by the drugs resulted in a marked prolongation of the median survival period (Fig. 2) . Untreated animals showed a survival time of 18.6 days. Treatment of the L5178y mice with 1.25 mg BLM/kg produced a 52 % increase in survival, with 2.5 mg BLM/kg an 110% increase and with 5 mg/kg an 84 % increase ( Fig. 2A) . PEP treatment at doses of 0.5 mg/kg, 1 mg/kg or 2.5 mg/kg resulted in a 67%, 110% or 39% increase of median survival time (Fig.   2B ). These data show, that the optimal doses of the drugs are for BLM 2.5 mg/kg and for PEP 1 mg/kg, under our experimental conditions chosen. A further increase of these doses reduced the median survival time, very likely as a result of drug toxicity. In the central part of the study, the antitumor activity of BLM and PEP given in combination was determined (Table 1) . Administration of one-fourth of the optimal dose of the drugs in combination (0.63 mg BLM/kg and 0.25 mg PEP/kg) revealed only a slight chemotherapeutic effect (18% increase of survival time), while a combination of one-sixth of the optimal doses resulted in a 100% increase of the median survival time. Thus, the combination of BLM+PEP provided a significant , synergistic tumor inhibitory effect (FIC index: 0.34). Even one-tenth of the two optimal doses showed a remarkable tumor inhibitory effect (56% increase of survival). The results also suggest, that the slight lifeprolongation rate of this two-drug-combination at one-half of the optimal doses may too be attributed to drug toxicity.
Discussion
If included in human polychemotherapy, BLM is administered in combination with methotrexatel17), with cyclophosphamide, vincristine and methyl-l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea18) and vinblastine19'.
These combinations are plausible also from the molecular point of view, because of the different molecular modes of action of these drugs. However, the main finding in this paper that PEP potentiates the antitumor effect of its structural analog BLM in the L5178y cell system in vivo came unexpectedly. We were stimulated to study this combination by our previous observations which showed that PEP potentiates the BLM-cancerostatic effect on L5178y cells in vitr9). Moreover, it was already known`' that on molecular level PEP causes preferentially single-strand breaks in DNA, while BLM degrades DNA by double-and single-strand breakages.
The degree of synergism caused by the BLM-PEP combination on L5178y cell growth in vivo was highly significant (FIC index: 0.34). Since we have not determined the combination effects in normal mice, the possibility exists that only a potency synergism has been elucidated. Future studies must clarify on the basis of maximum tolerated doses (performed both with normal and tumor-bearing mice), whether the combination effect, described in the present investigation, reflects a therapeuticor a pharmacological synergism20). PEP produced a higher subacute toxicity on mice than BLM.
This effect correlates with the in vitro data9) which also revealed a higher cytotoxic effect of PEP.
However, PEP has been demonstrated to cause a lower pulmonary toxicity at therapeutic doses than BLMT7. Consequently, the following two modes of application of PEP in cancer treatment might be deduced; firstly, as substitution for BLM and secondly, in the combination chemotherapy with BLM. However, the clinical utility of the PEP-BLM combination depends on the results of experimental studies which have to investigate, whether or not PEP "synergizes" also the pulmonary toxicity of BLM. 243 VOL.
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